C. auris, a type of yeast that can cause severe illness, is a “global health threat”, according to experts.
-
Bookmark
C. auris, a type of yeast that can cause severe illness, is a “global health threat”, according to experts.
Bookmark
Massachusetts startup Elemind has raised $12 million to read brainwaves and treat people for sleep disorders, long-term pain, tremors, and to speed up learning rates. Clinical trials show the company’s wearable device can accelerate sleep up to 70% faster, reduce tremors in patients with physiological shaking up to 50%, and boost learning rates.
“We use a wearable neurotech device to read the brain in real time and intercept it in real time with something called neurostimulation,” Elemind co-founder and CEO Meredith Perry told me on a recent TechFirst podcast. “That’s using sound or light or vibration or electricity to stimulate the brain. And when we do that, we can actually guide the brain precisely, and that leads to a behavior change. So like a drug, but much smarter and without the side effects.”
While combing through the human genome in 2007, computational geneticist Pardis Sabeti made a discovery that would transform her research career. As a then-postdoctoral fellow at the Broad Institute of MIT and Harvard, Sabeti discovered potential evidence that some unknown mutation in a gene called LARGE1 had a beneficial effect in the Nigerian population.
Other scientists had discovered that this gene was critical for the Lassa virus to enter cells. Sabeti wondered whether a mutation in LARGE1 might prevent Lassa fever—an infection that is caused by the Lassa virus, is endemic in West Africa, and can be deadly in some people while only mild in others.
To find out, Sabeti decided later in 2007, as a new faculty member at Harvard University, that one of the first projects her new lab at the Broad would take on would be a genome-wide association study (GWAS) of Lassa susceptibility. She reached out to her collaborator Christian Happi, now the Director of the African Center of Excellence for Genomics of Infectious Diseases (ACEGID) at Redeemer’s University in Nigeria, and together they launched the study.
In the future, modern machines should not only follow algorithms quickly and precisely, but also function intelligently—in other words, in a way that resembles the human brain. Scientists from Dortmund, Loughborough, Kiev and Nottingham have now developed a concept inspired by eyesight that could make future artificial intelligence much more compact and efficient.
They built an on-chip phonon-magnon reservoir for neuromorphic computing which has recently been featured as Editor’s Highlight by Nature Communications.
The human sensory organs convert information such as light or scent into a signal that the brain processes through myriads of neurons connected by even more synapses. The ability of the brain to train, namely transform synapses, combined with the neurons’ huge number, allows humans to process very complex external signals and quickly form a response to them.
We’ve updated our list of the best longevity experts on Twitter/X and added 8 new accounts, including Dr. Morgan Levine, Dr. Brad Stanfield, and the research journal Nature Aging!
Best known for his popular longevity YouTube channel, Stanfield is a medical doctor with an interest in longevity science. Like some other folks on this list of longevity influencers, Stanfield can be a bit iconoclastic, challenging orthodoxy on things like resveratrol and fisetin.
Just like in his well-sourced videos, Stanfield’s Twitter feed is heavy with links to research papers and studies on longevity-related topics, from recent mouse studies out of the Interventions Testing Program, to threads on diet based on new trials. The downside is in his Twitter feed you don’t get to hear that sweet Kiwi accent you get from his videos.
Followers: 24,000
Founder and CEO of AI drug discovery Insilico Medicine (which has raised over $400 million under his leadership), Alex Zhavoronkov seems to be everywhere in longevity circles. From serving on the board of Peter Diamandis’s X-Prize Foundation (which recently announced its longevity X-Prize), to founding biological age testing company Deep Longevity, to somehow having the time to publish over 170 peer-reviewed studies.
To show one of the advantages of being a cyborg, I typed my old prescription into ZEISS Optical Inserts which are for use with the Apple Vision Pro and it said “We are really sorry, but your prescription values go beyond the available range.”
But now that I’m a cyborg with artificial lenses, any optical inserts that I might need are very common and available.
Oh, I experimented a little and it looks like they can’t make lenses for −9.75 diopters or worse. My left-eye used to be −17.25!
We need your eyeglass prescription to create your ZEISS Optical Inserts – Prescription (sometimes also called distance prescription). This is why we ask you to upload it.
Contact lens prescriptions or ones for task-specific uses (office or computer glasses, near reading glasses) don’t qualify.
Immunotherapy has rapidly advanced the field of medicine and has saved countless lives. The approach is much different than using an external chemical, such as in the case of chemotherapy. Immunotherapy leverages the body’s own immune system to recognize and attack foreign pathogens, specifically cancer. While there are many versions of immunotherapy, one rising star among them is known as Chimeric Antigen Receptor (CAR) T cell therapy. This therapy (usually) takes a patient’s own cells in the blood to generate engineered immune or T cells to fight the tumor. T cells are a critical immune cell population responsible for killing or lysing infected cells. In the case of CAR T cell therapy, the T cells from the patient are engineered to recognize receptors on the tumor. The CAR T-cells are then triggered to release different proteins and lyse the tumor cells. This type of therapy has revolutionized the way we treat patients with hematopoietic malignancies or blood cancers.
CD4+ T cells have been highlighted in the scientific literature for the important role they play in the immune response to lung infections. However, an article published in the journal Cell Reports shows that an imbalance in the volumes of these defense cells in different parts of the lung in response to infection can do more harm than good.
The study described in the article involved infecting mice with hypervirulent tuberculosis and influenza. The authors concluded that an “ideal amount” of CD4+ T cells in the lungs was required for a cure.
This finding opens up perspectives for therapeutic interventions aimed at combating diseases that attack the lungs while not affecting the ability of the adaptive immune system to fight off infection. Even relatively small numbers of CD4+ T cells in the lungs proved sufficient to afford protection against tuberculosis, for example.